About Event
The 8th Complement-Based Drug Development Summit will reunite 100+ preclinical, translational, and clinical experts at the forefront of complement-based drug development.
With new excitement and energy in the complement field, following Novartis’ approval, join us to dig deep into strategic targeting within the complement cascade, mitigating toxicity, the potential for complement combinations and moving into inflammatory and autoimmune diseases beyond rare disease.
What's New?
1
Deep dive into complement inhibitors in the CNS and oncology with the Broad Institute, IgM Biosciences and Argenx to stay up to date as the complement field moves into new therapeutic areas
2
Examine the past, present and future of complement inhibitors for autoimmune conditions and how they may be combined with existing therapies with Sanofi, Apellis and Arizona State University
3
Highlight the role of Haem on the complement system with New York Blood Center to inform the development of complement inhibitors for rare blood disorders
Join Your Peers to:
Review strategic targeting and preclinical breakthroughs for the next generation of complement inhibitors and comprehensive insights into the complexities of the complement pathways and selection of inhibition targets
Navigate complement clinical trials and explore the strategic expansion of indications for complement inhibitors beyond their initial targets
Explore potential for combinations to overcome compensatory mechanisms and ensure patient comfort
Move from targeting rare disease with complement inhibitors to larger patient populations
Navigate efficacy and safety of complement inhibitors to bring safer and more tolerable therapies to patients faster
Who Will You Meet?
A highly focused audience comprising of executives working in discovery, preclinical, translational, clinical, PK/PD toxicology and medical affairs will enable unparalleled information sharing and brainstorming for those across the entire complement landscape including large pharma, biotech, and service providers.
